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The human DMTF1 (DMP1) transcription factor, a DNA binding protein that interacts with cyclin D, is a positive
regulator of the p14ARF (ARF) tumor suppressor. Our earlier studies have shown that three differentially spliced
human DMP1 mRNAs, α, β and γ, arise from the human gene. We now show that DMP1α, β and γ isoforms dif-
ferentially regulate ARF expression and promote distinct cellular functions. In contrast to DMP1α, DMP1β and γ
did not activate the ARF promoter, whereas only β resulted in a dose-dependent inhibition of DMP1α-induced
transactivation of the ARF promoter. Ectopic expression of DMP1β reduced endogenous ARF mRNA levels
in human ﬁbroblasts. The DMP1β- and γ-isoforms share domains necessary for the inhibitory function of the
β-isoform. That DMP1βmay interact with DMP1α to antagonize its function was shown in DNA binding assays
and in cells by the close proximity of DMP1α/β in the nucleus. Cells stably expressing DMP1β, as well as shRNA
targeting all DMP1 isoforms, disrupted cellular growth arrest induced by serum deprivation or in PMA-derived
macrophages in the presence or absence of cellular p53. DMP1mRNA levels in acute myeloid leukemia samples,
as compared to granulocytes, were reduced. Treatment of acute promyelocytic leukemia patient samples with
all-trans retinoic acid promoted differentiation to granulocytes and restored DMP1 transcripts to normal granu-
locyte levels. Our ﬁndings imply that DMP1α- and β-ratios are tightly regulated in hematopoietic cells and
DMP1β antagonizes DMP1α transcriptional regulation of ARF resulting in the alteration of cellular control with
a gain in proliferation.
© 2015 Elsevier B.V. All rights reserved.
1. Introduction
The 761-amino acid cyclin D-binding myb-like protein (DMTF1;
DMP1) was originally identiﬁed as a cyclin D binding protein with
ETS-like transcription factor motifs [1]. Subsequently, it was found to
be a positive transcriptional regulator of CD13/APN and the p14ARF
(ARF) tumor suppressor [2,3]. DMP1-mediated transcriptional activa-
tion of ARF gene increases ARF protein levels, which in turn binds
MDM2 and blocks the cellular removal of p53 [4–6]. Furthermore,
DMP1 can physically interact with p53 antagonizing the ubiquitination
function of MDM2, therebymaintaining p53 levels [7]. Our earlier stud-
ies have shown that DMP1 is comprised of three differentially spliced
human DMP1mRNAs, DMP1α, β, and γ, which have unique expression
patterns in normal, primary hematopoietic cells during differentiation
[8]. The β and γ protein isoforms lack the DNA binding and C-terminal
transactivation domains [8].While DMP1α can function as a tumor sup-
pressor and activate the CD13/APN and ARF promoters [2,3], DMP1β
and γ have lost the capacity to function as CD13/APN transcriptional ac-
tivators [8]. Recently, DMP1β was reported to be present in selected
human breast cancer tissues, extending cell types expressing differen-
tially spliced DMP1 [9].
DMP1 is emerging as pivotal protein possibly linking Ras/Raf/ERK
growth promoting signals with the ARF/p53/p21 tumor suppressor
network [10]. Studies in mDmp1-null and -heterozygous mice have
implicated a critical and physiological role for mDmp1 in decreasing
the incidence of leukemia and non-hematopoietic tumors [11]. Consis-
tent with the role of mDmp1 in controlling oncogenic insults is the
dramatically accelerated lymphomagenesis seen in mDmp1-null and
-heterozygous mice in the presence of the oncogenic Eμ-Myc transgene
[12]. Moreover, tumors can develop in mice without p53 mutations
or ARF deletions, further emphasizing the regulatory importance of
mDmp1 in p53 as well as non-p53 pathways [5,12]. In human non-
small lung cell carcinomas, loss of heterozygosity of DMP1 was found
Biochimica et Biophysica Acta 1849 (2015) 1198–1208
☆ Financial support: This work was supported by Grants from NIH (DK49886, AI49165,
and HL091219 to B.E.T.; CA131231 and CA172115 to P.S.) and from the Swiss National
Science Foundation (31003A_143739 to M.P.T. and PBBEP3_146108 to E.A.F.).
⁎ Corresponding author at: Department of Molecular and Experimental Medicine,
MEM-131, The Scripps Research Institute, 10550 North Torrey Road, La Jolla, CA, USA.
E-mail address: betorbet@scripps.edu (B.E. Torbett).
http://dx.doi.org/10.1016/j.bbagrm.2015.07.009
1874-9399/© 2015 Elsevier B.V. All rights reserved.
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbagrm
in about 35% of the cancers evaluated (n = 51), which was mutually
exclusive with mutations of p53 and/or Arf/ink4a [13]. These ﬁndings
further underscore the importance of DMP1 in human oncogenic
suppression.
hDMP1 is located on chromosome 7q21, a locus frequently altered
in human acute myeloid leukemia (AML) and breast cancer [14–17].
Studies in Dmp1-null mice demonstrated a gain of proliferative function
in hematopoietic stem and common myeloid progenitor cells, thus
uncoupling cellular control of blood lineages that can give raise to
leukemias [18]. That DMP1β has a function distinct from DMP1α in
controlling cell progression was shown by its capacity to promote prolif-
eration in macrophages, which are limited in proliferation after differen-
tiation frommonocytes [8]. The identiﬁcation of increased DMP1β levels
over α in human breast cancers and the promotion of mammary tumors
inMMTV-DMP1β transgenemice, supports a disease progressive role for
DMP1β, rather than the tumor suppressor function of DMP1 [9].
To interrogate the transcriptional and cellular roles of the β and γ
DMP1 isoforms, we investigated their capacity to transactivate the
ARF promoter, regulate endogenous ARF, and enhance proliferation.
Our ﬁndings deﬁne a transcriptional pathway whereby the DMP1β iso-
form, but notγ, can dampenDMP1α-mediated ARF responses in a dom-
inant negative fashion.Moreover, theDMP1β isoform supports a gain of
cellular proliferation in the presence or absence of p53. Lastly, DMP1
message levels in primary acute myeloid leukemia samples, as com-
pared to granulocytes, were signiﬁcantly reduced. We propose that
DMP1β antagonizes the function of DMP1α, thus altering cellular prolif-
erative control.
2. Material and methods
2.1. Plasmids and lentiviral vectors
2.1.1. Human and mouse DMP1/EGFP cloning
The open reading frames of all three DMP1 isoforms were PCR am-
pliﬁed and TOPO cloned using the following primers: general forward
primer 5′-GAAGCTTGCCGCCACCATGAGCACAGTGGAAGAGGATTC-3′,
and the human α-speciﬁc 5′-GCCGCGGATGACAGTTTACCAAATCTTCG
AC-3′, human β-speciﬁc 5′-GCCGCGGTTCTTCATTCTTCTTCTTCCCATTTG
AC-3′, human γ-speciﬁc 5′-GCCGCGGTTCTTCATTCTTCTTCTTCCCATTT
GAC-3′ reverse primers, mouse β-speciﬁc 5′-GCCGCGGTTCTTCATTCT
TCTTCTCCCTTCTGAC-3′ or γ-speciﬁc 5′-GCCGCGGTTCTTCATTCTTCTTC
TTCCCATTTGAC-3′ reverse primers. The HindIII/SacII fragments were
further subcloned into pEGFP-N1 resulting in DMP1 isoforms fused to
enhanced green ﬂuorescent protein (EGFP). A generic Kozak element
was added for efﬁcient transcription in mammalian cells.
2.1.2. Human DMP1 ΔMHR cloning
The sequence encoding amino acids 1 to 223 of DMP1αwas PCR am-
pliﬁed using the forward primer described above and the 5′-GCCGC
GGATGGTTTCTGTCATCATACATGC-3′ reverse primer. The PCR product
was TOPO cloned and the HindIII/SacII fragment was further subcloned
into pcDNA3.1/V5/His. Cloning of the V5/His tagged DMP1α, β and γ
expression vectors were described earlier [8].
2.1.3. Generation of the CGW lentiviral vector
The self-inactivating (SIN) CGW control vector was assembled by
standard cloning techniques from the following elements:MND,myelo-
proliferative sarcoma virus LTR-negative control region deleted; cPPT-
CTS, polypurine tract–central terminating sequence; IRES, internal
ribosome entry site; EGFP, enhanced green ﬂuorescent protein; SAR,
IFN-β-scaffold attachment region; and WPRE, woodchuck hepatitis
virus posttranscriptional regulatory element. The vector backbone was
derived from CS-PRE, a derivative of HIV-CS (kind gift of H. Miyoshi,
University of Tsukuba, Japan), which has unique BamHI, SacII, EcoRI,
XbaI, HpaI, and XhoI sites upstream of the WPRE. The MND LTR was
cloned from the MND-HSPSV-EGFP plasmid (kind gift of D. Kohn, USC
School of Medicine, Children's Hospital, Los Angeles, CA) and cloned
into the BamHI site. The 178-bp cPPT-CTS BamH1/Sma1 fragment was
ampliﬁed from HIV-1 molecular clone R8. The viral IRES and EGFP frag-
ment were cloned from plasmid pIRES2-EGFP (Clontech, BD Biosci-
ences). The 800 bp 3′ scaffold attachment region (SAR) element was
cloned from plasmid pCL, by introducing Xba1/Hpa1 sites [8].
2.1.4. CGW-hDMP1β and pBABE-hDMP1β-puro cloning
ThehumanDMP1β open reading framewas PCR ampliﬁed (primers:
forward 5′-AAGCTTGCCGCCACCATGAGCACAGTGGAAGAGGATTC-3′
and reverse 5′-CCGCGGTTCTTCATTCTTCTTCTTCCCATTTGAC-3′), TOPO
cloned and further subcloned into the EcoRI site of CGW (Suppl.
Fig. 5A, top) or the HindIII/SacII sites of pBabe-puro [19].
2.1.5. CGW-shDMP3 and shDMP5 lentiviral vector cloning
The U6 promoter driven short hairpin (sh)RNA expression cassettes,
shDMP3 and shDMP5, targeting the open reading frame or the 5′ untrans-
lated region (Suppl. Fig. 5B, bottom), respectively, were PCR cloned using
the pTZU6+1 hp plasmid (kindly provided by Dr. J.J. Rossi, Beckman Re-
search Institute, City of Hope, Duarte, CA) as template and the following
primers: forward 5′-GGATCCAAGGTCGGGCAGGAAGAGGG-3′ and re-
verse 5′-GCTGCAGAAAAAATAAATGGAAGCAGGGGATGTGTCTCTTGAACA
CATCCCCTGCTTCCATTTACGGTGTTTCGTCCTTTCCAC-3′ for shDMP3 and
5′-GCTGCAGAAAAAAGCACTTTGGAAGAACCAGGATTCTCTTGAAATCCTG
GTTCTTCCAAAGTGCCGGTGTTTCGTCCTTTCCAC3′ for shDMP5. Comple-
mentary shRNA sequences are underlined. The PCR fragment was TOPO
cloned into pCR-XL-TOPO (Invitrogen) and the BamHI/PstI fragment
was further subcloned 5′ of the MND promoter into the CGW vector.
2.1.6. pLKO.1 shDMP1
pLKO.1 lentiviral vectors expressing small hairpin (sh)RNAs targeting
human DMTF1 (shDMTF1_375: NM_021145.1-375s1c1, shDMTF1_888:
NM_021145.1-888s1c1, shDMTF1_2148: NM_021145.1-2148s1c1 and
shDMTF1_2248: NM_021145.1-2248s1c1) or a non-targeting shRNA
control (SHC002)were purchased fromSigma-Aldrich. Lentiviral produc-
tion and transduction of the different cells was done as described [8].
2.2. Cell lines, primary cells and generation of stable transfectants
U937 and 293T cells were maintained in DMEM; MOLM-13, NB4,
HT93 and HL60 cells in RPMI supplemented with 10% fetal bovine
serum (FBS), 100U/ml penicillin and streptomycin, and 2mMglutamine,
at 37 °C in 5% CO2. Cells were serum-starved by incubation in 0.1% FBS
containing medium after ﬁve washes with PBS. For themyeloid differen-
tiation experiments, we used the human acute leukemia cell lines U937,
MOLM-13 and HL60 or the human APL cell lines NB4 and HT93.
Cells were seeded at a concentration of 2 × 105 cells/ml and treated
with phorbol 12-myristate 13-acetate (PMA) as indicated or with 1 μM
all-trans retinoic acid (ATRA). Cell culture reagents, media and
differentiation-inducing agents were purchased from Sigma-Aldrich.
Peripheral granulocytes were isolated from buffy coats of healthy
donors recruited at the Inselspital Bern, Switzerland, using Ficoll gradi-
ent density centrifugation (Lymphoprep, Axon Lab AG, Switzerland).
Red cells in the bottom layer were treated with erythrocyte lysis buffer
(Qiagen AG, Hombrechtikon, Switzerland) to yield a granulocytes frac-
tion enriched (N95% purity). Fresh leukemic blast cells from AML
patients at diagnosis obtained at the University Hospital Inselspital
Bern were classiﬁed according to the French–American–British (FAB)
classiﬁcation and cytogenetic analysis. Informed consent was obtained
from all patients. All leukemia samples had blast counts N90% after
separation of mononuclear cells using a Ficoll gradient as described
previously [8]. All protocols for the use of human sample uses were
approved by the Cantonal Ethical Committee at the Inselspital and The
Scripps Research Institute.
Normal human foreskin ﬁbroblasts (BJ) and lung ﬁbroblasts
(IMR90) were maintained in 6-well plates and infected with
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pBabe-puro and pBabe-puro-hDMP1β retroviral particles produced
in LinX-A amphotropic packaging cells. After 48 h, cells were trans-
ferred to 100-mm dishes. Selection of stable cells was carried out in
the presence of 1.0 μg/ml puromycin for oneweek. Lentiviral produc-
tion and transduction of 293T, HeLa and U937 cells were done as
described [8].
2.3. Transient transfections and reporter assays
293T cells were transiently transfected with pGL2 reporter plasmids
containing an ARF promoter fragment (pGL2-ARFpro), an ARF promoter
fragment with a mutated DMP1 consensus site (pGL2-ARFpro mutant)
or a stretch of eight concatemerized DMP1 binding sites (pGL2-BS2) up-
stream of the ﬁreﬂy luciferase reporter gene (kindly provided by Dr. C.J.
Sherr, St. Jude Children's Hospital, Memphis, TN) and the different
human or mouse DMP1 isoform expression plasmids. Total DNA was
kept constant with parent vector. Cells were lysed forty-eight hours
after CaPO4 transfection and were assayed for luciferase activity by a
Dual-Luciferase™ Reporter System kit (Promega) [8]. Transfection
efﬁciencies were normalized with an internal Renilla expressing plasmid
(pRL-TK). Results, expressed as ratio of Fireﬂy toRenilla luciferase (relative
luciferase activity, RLA), are themeans of three independent experiments
measured in duplicate, and error bars represent standard deviations.
2.4. RNA extraction, human DMP1 variant speciﬁc RT-PCR and total human
DMP1 qPCR assays
RNA extraction and cDNA synthesis were done as described [8]. The
following primer and probe combinations were used to analyze the
house keeping gene ABL, forward 5′-TGTGGCCAGTGGAGATAACACT-
3′; reverse 5′-CCATTCCCCATTGTGATTATAGC-3′; probe 6FAM-5′-TAAG
CATAACTAAAGGTGAAAAGCTCCGGGTCTTA-3′-TAMRA. For ARF, we
used primers and a probe as described [20]. All samples were run
under standard conditions on a 7900HT sequence detection system
(Applied Biosystems).
To determine human DMP1 expression we used the following three
assays: First, to quantify total hDMP1 gene expression the Taqman®
Gene Expression Assays preloaded on low density arrays for hDMP1,
HMBS and ABL1 were Hs00253517_m1, Hs00609297_m1 and
Hs00245445_m1, respectively. Data were normalized to HMBS and
ABL1 and analyzed as described [21]. Second, to speciﬁcally quantify
hDMP1 α and β we used hairpin-unfolding-based RT-PCR [22]. The
following primers were used: hDMP1α as described in Blancafort P
et al. [23]; hDMP1β forward 5′-actgaacctgaccgtacaATTGAGAAGCTC
AAGGAACAACTGT-3′, reverse 5′-CCATTTGACTGGTTGGAAGTTG-3′,
ABL1 forward 5′-actgaacctgaccgtacaTGCCCTGCATTTTATCAAAGG-3′; re-
verse 5′-AAAGTCAGATGCTACTGGCCG-3′. The 5′ end of the target specif-
ic forward primer contains a tail sequence complementary to the 3′ end
of the UniPrimer (see nts depicted in lower case) (EMD, Millipore). Ex-
pression was quantiﬁed according to the comparative threshold meth-
od using the formula 2−ΔΔCt, where ΔΔCt = ΔCt(sample) −
ΔCt(calibrator), and ΔCt is the Ct of the target gene subtracted from
the Ct of the house keeping gene ABL1 [24,25]. Unfortunately, this
hDMP1β assay, also highly speciﬁc, was not sensitive enough to reliably
quantify endogenous expression of this splice variant. Thus, we only
used this assay to conﬁrm β-speciﬁc overexpression in transduced BJ
and IMR90 cells. Third, we used a single primer pair encompassing the
β/γ insertions to determine relative expression of the hDMP1 splice
variants. This assay allows differentiation of the three isoforms based
on size differences of the resulting PCR product and has been published
earlier [8].
2.5. Band shift assays
Band shift assays were done as described [26]. Brieﬂy, DMP1
isoform proteins were in vitro synthesized using rabbit reticulocyte
lysates (TnTQuick Coupled Transcription/Translation System, Promega,
USA). Annealed probes were radioactively labeled using 50 μCi of aden-
osine 5′-[γ32P]triphosphate at 6000 Ci/mmol (Amersham) and T4-
Polynucleotide Kinase (Life Technology Invitrogen, USA). A probe
containing the putative DMP1 binding site in the human ARF promoter
(5′-GTCAGGTGACGGATGTAGCTAGG-3′) was used. Binding reactions
were carried out in a total reaction volume of 15 μl containing 100 ng
poly-(dIdC), 1 μl hot probe, 5 μl of programmed reticulocyte lysate,
200 ng of monoclonal anti-V5 antibody (Life Technology), and compet-
ing cold oligonucleotides where indicated, in binding buffer (10 mM
TrisHCl (pH 8.0), 250 mM KCl, 500 μM EDTA, 0.1% Triton-X 100, 12.5%
glycerol (v/v), 200 μM DTT) for 30 min at room temperature. Protein–
DNA complexes were separated on 4% non-denaturing PAGE for
90 min at 1 mA/cm at 4 °C. Gels were dried and exposed to Kodak
BioMax XAR Films at−80 °C. Band densities were determined using
ImageQuant Software (GE Healthcare, USA).
2.6. Proximity ligation assay
To detect a possible interaction betweenDMP1α andβ aswell as be-
tween DMP1α/β and p53, we utilized the DuoLink in situ Proximity Li-
gation Assay (PLA) [27] according to the manufacturer's protocol
(Sigma). Transient transfection of 293T cells was done using lipofecta-
mine (Invitrogen), then, cells cultured on glass coverslips, were ﬁxed
with 4% PFA followed by 10 min incubation with 0.1% Triton X-100 so-
lution in PBS and further blocked with PBS-containing 1% BSA and 0.1%
Tween. Cells were immunolabeled with the following primary antibod-
ies: V5-Probe (Santa Cruz; sc-81594) and EGFP (Santa Cruz; sc-8334)
for 1 h at room temperature. Secondary antibodies with attached PLA
probes speciﬁc to the primary antibodies were supplied by the manu-
facturer. We used confocal microscopy to detect protein-to-protein in-
teraction at a 60× magniﬁcation. A ﬂuorescence signal indicates that
two proteins within cells are separated by b40 nm.
2.7. Confocal microscopy
293T and HeLa cells were grown on poly-L-lysine-coated glass cov-
erslips and transiently transfected with expression plasmids containing
DMP1β or γ C-terminally fused with EGFP. After 24 h, the cells were
washed four timeswithHBSS. Cellswere thenﬁxedwith 2% paraformal-
dehyde, washed once with PBS and treated with DNAse-free RNAse for
15 min at room temperature. After washing twice with PBS, the nuclei
were stained with TO-PRO 3 (1:2000; Molecular Probes). The cells
were examined using a laser confocal scanning microscope (BioRad).
Images were processed using Adobe Photoshop (Adobe Systems).
2.8. Western blot analysis as well as cytoplasmic and nuclear fractionation
Whole cells were lysed in urea buffer consisting of 8 M urea and
0.5% Triton X-100 supplemented with protease inhibitor cocktail
(Roche). 30 μg of total protein was analyzed by electrophoresis on a
mini-protean TGX Stain-Free Precast gel (Bio-Rad). Antibodies used
were anti-EGFP rabbit polyclonal antibody (Molecular Probes, Basel
Switzerland) and goat anti-rabbit IRDye® 800CW (Li-Cor Biosciences).
Blots were analyzed using the Odyssey infrared imaging system detec-
tion (Li-Cor Biosciences).
Cytoplasmic and nuclear fractionation was done by ﬁrst lysing the
cells in buffer A (HEPES 10 mM (pH 8.0), KCl 10 mM, MgCl2 1.5 mM,
DTT 1 mM), centrifugation and recovering the supernatant. The cell
pellet was re-suspended in buffer B (HEPES 20 mM (pH 8.0), MgCl2
1.5 mM, KCl 400 mM, NaCl 40 mM, EDTA 0.2 mM, DTT 1 mM, glycerol
25%) to lyse the nuclear envelope and nuclear proteins were extracted.
Protein content was determined with a Bradford Assay (#500-0006;
Bio-Rad)with BSA as a standard. 5 μg of cytoplasmic andnuclear protein
was analyzed by electrophoresis on a mini protean TGX Precast gel
(Bio-Rad). Primary antibodies used were anti-α-Tubulin (#3873; Cell
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Signaling), anti-Histone H3 (#9715; Cell Signaling), and anti-EGFP (see
above). Secondary antibodies usedwere anti-rabbit and anti-mouse IgG
HRP-linked (NA93IV; GE Healthcare). Chemiluminescence signal was
detected using an ECL-kit (170-5060; Bio-Rad).
2.9. Proliferation assays
Proliferative capacity was assessed by [3H]thymidine or bromo-
deoxyuridine (BrdU) incorporation. 293T, HeLa and U937 transfectants
were plated in 96-well plates at concentrations of 7.5 × 103 and
15 × 103/well and were incubated for serum conditions as indicated.
[3H]thymidinewas added for the last ﬁve hours of cell treatment (1 μCi/
well). Cells were harvested using aMach III cell harvester (Tomtec) and
γ-radiation was detected using a Wallac 1450 MicroBeta Liquid
Scintillaton Counter (PerkinElmer). For the BrdU incorporation analysis,
HL60 andMOLM-13 cells were cultured in 24-well plates and treated as
indicated. BrdU incorporationwasmeasured using the BrdU cell prolifer-
ation assay kit (Cell Signaling). Subsequent immunoﬂuorescent staining
of incorporated BrdU was followed by ﬂow cytometric analysis using
the BrdU Flow Kit (BD Biosciences, San Jose, CA, USA).
3. Results
3.1. Transcriptional activities of the human DMP1 isoforms
Wehave reported earlier on the splicing and resulting protein struc-
tures of the DMP1α, β and γ isoforms [8] and see Suppl. Fig. 1 for a
DMP1 isoform diagram). Similar to our earlier ﬁndings utilizing the
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
A
7
6
5
4
3
2
1
0
B 40
35
30
25
20
15
10
5
0
1.2
1.0
0.8
0.6
0.4
0.2
0.0
BJ IMR90
0.0E+04
0.5E+04
1.0E+04
1.5E+04
2.0E+04
C D
BJ IMR90
Fig. 1. Human DMP1β negatively regulates p14 ARF transactivation. A) Transcriptional response of the ARF promoter to the different DMP1 isoforms. 293T cells were transiently
transfected with 4 μg of each reporter plasmid, 10 ng of the Renilla luciferase expression plasmid pRL-TK and with increasing amounts of the DMP1 isoform expression plasmids
pcDNA3.1–DMP1α, β, γ or the control expression vector pcDNA3.1. The promoter activity is shown as relative luciferase activity (RLA). Results are themeans± S.D. of triplicate transfec-
tions. B) Primary human foreskin ﬁbroblasts were transfectedwith expression vectors as in (1A). ARF transcripts weremeasured by qPCR. Speciﬁc gene expressionwas normalized to ABL
expression. Results are given as fold expression of pcDNA3.1 transfected cells. The experimentwasperformed induplicate. C) Co-expression of DMP1β andγwithDMP1α and its inﬂuence
on ARF promoter activity. 293T cells were transiently transfected with 4 μg of each reporter plasmid, 10 ng of the Renilla luciferase expression plasmid pRL-TK, 1.5 μg pcDNA3.1–DMP1α
andwith increasing amounts (1.5, 3.0 and 6.0 μg) of the pcDNA3.1–hDMP1β or γ plasmids. Analysis was performed as described above. D) Retroviral expression of DMP1β in BJ or IMR90
primary human ﬁbroblasts reduces endogenous ARF mRNA levels. Cells were transduced with empty (BP) and DMP1β expressing (BP-hDMP1β) pBabe-puro retroviral vectors. ARF and
DMP1βmRNA levels of puromycin selected cell populations were measured by qPCR and normalized to ABL expression. Results are given as fold expression of mock-transduced cells.
Mean and standard deviation (bars) is shown.
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CD13/APN promoter [8], DMP1α, but not β or γ, activated the ARF pro-
moter (Fig. 1A). In contrast to DMP1α or γ, increasing the amounts of
exogenous DMP1β inhibited basal levels of ARF promoter activity. An
ARF promoter reporter with a mutated DMP1 binding site, pGL2-
ARFpro mutant, was used as negative control and showed no changes
in activity when co-expressed with DMP1α, conﬁrming the speciﬁcity
of DMP1α transactivation. Studies utilizing plasmid expression of
DMP1α, β and γ EGFP fusion proteins indicated that each isoform was
present in cells after transient transfection (Suppl. Fig. 2A and B).
To assess whether endogenous cellular ARF can be regulated by the
different DMP1 splice variants, we transiently expressed the splice
variants in human primary BJ ﬁbroblasts (Fig. 1B).We found a 30-fold in-
duction of ARF mRNA levels in cells expressing DMP1α, conﬁrming that
elevated cellular levels of humanDMP1α indeed caused increased endog-
enous ARF transcription. Similar to the ﬁndings in transient transfection
assays with the ARF promoter, DMP1β and γ did not induce ARF tran-
scription in primary ﬁbroblasts. Given the ﬁndings shown in Fig. 1A and
B, we next evaluated whether DMP1β and γ could inhibit DMP1α-
induced activation of the ARF promoter. Cellular co-transfection of
DMP1β with α resulted in a dose-dependent inhibition of DMP1α-
induced transactivation of the ARF promoter (Fig. 1C, left). In contrast,
DMP1γ did not signiﬁcantly inhibit the ARF promoter activity induced
by DMP1α (Fig. 1C, right), which is in agreement with our earlier pub-
lished ﬁndings utilizing the CD13/APN promoter [8]. To determine if spe-
cies conservation was apparent for DMP1, the mouse Dmp1β gene was
scrutinized and an alternative splice acceptor site was identiﬁed (Suppl.
Fig. 3A). Furthermore, the mouse β-isoform showed similar α inhibitory
functions as the human isoform in DMP1 promoter transactivation re-
porter assays (Suppl. Fig. 3B). These results indicate that either the
human or mouse DMP1β isoform antagonizes the transcriptional activity
of theα-isoform. The species conservation of the alternative splice accep-
tor sites, protein, and function in human and mouse supports the poten-
tial cellular relevance of the β-isoform.
Next, we analyzed the effects of ectopically expressed DMP1β on
endogenous ARF mRNA levels in human primary ﬁbroblasts. Since
the DMP1γ splice variant had minimal effect on antagonizing the tran-
scriptional activation functionofDMP1α (Fig. 1C, right panel),we focused
our effort onDMP1β. Stably retroviral transducedhumanBJ and IMR90ﬁ-
broblast cell lines were generated using the pBabe-hDMP1β-puro (BP-
hDMP1β), with the empty pBabe-puro (BP) retroviral vector as the con-
trol. After selection in puromycin we measured endogenous ARF levels
by qPCR. We found an 80% downregulation of ARF in BJ and IMR90 cells
expressing DMP1β as compared to the controls (Fig. 1D, left panel). We
conﬁrmed that the BP-hDMP1β transduced cells expressed 1.2 to
1.4 × 104 fold higher DMP1β levels than the BP control cells (Fig. 1D,
right panel). Thus, continued ectopic expression of DMP1β in ﬁbroblasts
leads to damping of endogenous ARF mRNA levels.
3.2. Functional analysis of the truncated human DMP1 isoforms
The ARF promoter results imply that DMP1β antagonizes DMP1α
activity. In contrast, DMP1γ does not affect transcriptional activity of
DMP1α. The noted difference between the two short isoforms is the
presence of 13 additional amino acids from intron 9 in DMP1γ as the
result of an alternative splicing, which joins the N-terminal and
C-terminal Myb-like homology domain remnants (Suppl. Fig. 1). We
reasoned that the functional differences between DMP1β and γmight
lie in this 13-amino acid sequence that is unique to the γ isoform
(Suppl. Fig. 1). To better understand the role of the C-terminal Myb-
like homology domain remnants (MHR), we compared the DMP1
MHR deletion mutant (ΔMHR), a mutant that lacks amino acids com-
mon to all three splice variants, to DMP1β and γ in a cell-based reporter
assay, and measured the degree of inhibition of DMP1α transcriptional
activity. Ectopic expression of DMP1α enhanced promoter reporter
activity beyond the endogenous cellular activity,whereas co-ectopic ex-
pression of DMP1β and DMP1α resulted in high-level (80%) inhibition
of DMP1α activity (Fig. 2A). The co-transfections of the ΔMHR mutant
or DMP1γ with DMP1α and promoter reporter demonstrated similar
low levels of inhibitory activity. These results indicate that the β-
speciﬁc protein sequence is necessary for efﬁciently inhibiting α func-
tion, as the N-terminal transactivation and cyclin D-binding domain,
and Myb-homology region common to all three DMP1 isoforms did
not confer high levels of DMP1α inhibition.
Although DMP1γ differs from DMP1β by the addition of only 13
additional amino acids (Suppl. Fig. 1), it demonstrated distinct functional
properties. Since nuclear localization is critical for DMP1 function, we
wondered whether the differences in DMP1 isoform activity could be
the result of cellular localization [28]. To investigate this possibility, we
compared subcellular localization of DMP1β and γ isoforms by confocal
microscopy. Since veriﬁed commercial antibodies are not available to dif-
ferentiate the subcellular localization of endogenous DMP1β and γ from
DMP1α, we transfected 293T and HeLa cells with different C-terminal
EGFP-tagged versions of the DMP1 isoforms. Surprisingly, unlike the nu-
clear speciﬁc localization of DMP1α- [28] and β-EGFP fusion proteins,
the DMP1γ signal was detected in the cytoplasm and nucleus, similar to
the EGFP only control (Suppl. Fig. 4A). Therefore, DMP1γ appears to
have an altered localization pattern relative to the other DMP1 isoforms.
Next, we quantiﬁed DMP1–EGFP isoforms from cytoplasmic and nuclear
compartments and determined that the γ protein isoformwas less abun-
dant than either the α- or β-isoforms, as evidenced by Western blot de-
tection of the respective DMP1–EGFP fusion proteins (Suppl. Fig. 4B).
Thus, DMP1γ cellular levels and, most importantly, nucleus localization
are decreased relative to the DMP1α- or β-isoforms. These ﬁndings may
provide a potential explanation for the lack of cellular DMP1γ activity ob-
served during our DMP1 splice variant transfection and ectopic expres-
sion studies. Lastly, it should be pointed out that our earlier report [8],
and a recent report by Maglic and colleagues [9], determined that in
many cell types DMP1γ transcripts were not abundant, relative to
DMP1α and β. Moreover, DMP1γ transcript levels remained constant
during human hematopoietic cell differentiation [8].
Next,we askedwhether the inhibitory activity of DMP1β is dependent
on direct binding to the DMP1 site present in the ARF promoter. To this
endwe performed electrophoretic mobility shift assays (EMSAs) utilizing
in vitro transcribed and translated V5-tagged DMP1α, β, or γ protein or
the ΔMHR (Suppl. Fig. 1). Only the α, but not the β and γ isoforms or
ΔMHR, was able to bind to a probe containing the DMP1 binding site of
the ARF promoter that resulted in a gel shift (Fig. 2B).Moreover, the addi-
tion of a monoclonal antibody directed against the V5-tag led to a
supershift of the DMP1α-probe complex, further conﬁrming interaction
speciﬁcity. In contrast, addition of a 300-fold molar excess of cold probe
efﬁciently blunted the shift. Cell lysates from the control empty
expression vector or the ΔMHR mutant failed to promote gel shifts, as
would be expected. Lastly, co-incubation of DMP1α with increasing
amounts of DMP1β decreased it's binding to the DNA probe to approxi-
mately 43% of DMP1α only (Fig. 2C). Our ﬁndings infer that DMP1α re-
quires MHR-TAD for binding to DNA, the shorter isoforms do not bind
the ARF promoter, and ﬁnally, DMP1β antagonizes DMP1α binding to
DNA.
To determine if DMP1α/α and α/βwere in close proximity in a cel-
lular environment and co-localized to the nucleus, we utilized in situ
proximity ligation methodology [27]. The proximity ligation method
depends on the dual proximal binding by pairs of detection reagents
to generate ampliﬁable DNA strands, which then can serve as markers
for the detection of 2 proteinswhen they are b40 nmapart.We ﬁrst de-
termined that transient ectopic expression of DMP1α-EGFP and
DMP1α-V5 were localized to the nucleus and DMP1α/α co-localized
based on signal proximity (Fig. 2D, top row). Next, DMP1α-EGFP and
DMP1β-V5 were evaluated in the same methodological fashion and
found to generate a similar ﬂuorescent signal pattern as seen with
DMP1α/α (Fig. 2D, middle row). These results indicate that DMP1α/α
and α/β co-localized within the nucleus and were within 40 nm of
each other [27].
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3.3. Human DMP1β provides a growth advantage in low serum conditions
and during myeloid differentiation
Given our ﬁndings that DMP1β dampens DMP1α-induced
transactivation of ARF,we directly testedwhether either ectopic expres-
sion of the β-isoform or directly decreasing DMP1α levels altered
growth patterns of 293T cells and the myelomonocytic cell line, U937,
in tissue culture. To this end, stably transduced cell lineswere generated
utilizing lentiviral vectors expressing EGFP, as a reporter only control,
the DMP1β–EGFP fusion protein, or two different short hairpin (sh)
RNAs targeting the DMP1 open reading frame (shDMP3) or the 5′ UTR
(shDMP5) (Suppl. Fig. 5A). Targeting only DMP1α is not possible given
all splice variants share the α sequence (Suppl. Fig. 1). All cell lines
utilized expressed the α-isoform and the lentiviral vector expression
of the DMP1 shRNAs reduced DMP1 mRNA levels 60% and resulted in
signiﬁcant inhibition of a DMP1α speciﬁc luciferase reporter (data not
shown).
The shRNA lentiviral vector stable expressing cell lines were
enriched for EGFP expression by ﬂow cytometry sorting and then tested
in a proliferation assay ([3H]-thymidine incorporation) in reduced
(0.1%) serum levels. Low serum levels are known to reduce proliferation
and survival in selected cell lines and the ectopic expression of certain
oncogenes has been shown to reverse this condition. What was readily
apparentwhen 293T and U937 cells expressing the β-isoformwere cul-
tured with low serumwas a signiﬁcant growth advantage as compared
to the control lines expressing just EGFP (Fig. 3A). Similar results were
obtained with HeLa cells expressing DMP1β (data not shown). Evalua-
tion of 293T or U937 cells in low serum revealed that stably expressing
shDMP3 or 5 enhanced cell proliferation in a manner similar to cells
ectopically expressing the DMP1β isoform (Fig. 3A). Increased cellular
proliferation as determined by [3H]-thymidine incorporation was fur-
ther conﬁrmed by cell counting (Fig. 3B). Thus, decreasing DMP1 levels
or increasing DMP1β levels conferred similar cellular traits of increased
proliferation in cultured cells maintained in low serum conditions.
During earlier studies on the role of DMP1α and β in CD13/APN
regulation and myeloid differentiation, we noted that the U937 cell
line treated with PMA underwent morphological differentiation, but
maintained proliferation when DMP1β was ectopically expressed [8].
To further interrogate the role of DMP1 during monocyte to macro-
phage differentiation and gain of proliferative function in macrophages,
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we differentiated U937 shDMP3, DMP1β, and EGFP (empty vector) ex-
pressing cells with PMA (Fig. 3C). When EGFP expressing control cells
were treated with increasing amounts of PMA (1, 3, 10 nM, and refer
to Fig. 3A for proliferation without PMA-mediated differentiation),
cells decreased proliferation (Fig. 3C), and underwent terminal differen-
tiation (not shown). In contrast, U937 shDMP3 or DMP1β expressing
cells continued to proliferate despite terminal macrophage differentia-
tion (Fig. 3C). Morphologically, PMA-treated U937 cells appeared simi-
lar whether cells were expressing shDMP3, DMP1β, or EGFP (data not
shown). Thus, loss of DMP1 or DMP1β ectopic expression provided for
a gain of proliferation in U937 macrophages.
DMP1 regulates p53 through ARF or directly via physical interaction
with p53 [2,7]. Furthermore, ARF has been reported to regulate tumor
suppression independently of p53 (reviewed in [5]) and a recent report
postulates that DMP1β may function independently of the ARF-p53
pathway [9]. To determine if loss of p53 alters macrophage proliferation
when DMP1 was disrupted, we utilized the U937 cell line, which has a
disruptive 46 amino acid deletion in the p53 gene [29]. As a control
for the wild type p53 gene we utilized the myelomonocytic MOLM-13
cell line [30]. PMA treatment of a MOLM-13 cell line expressing scram-
bled shRNAs from integrated lentiviral vectors demonstrated loss of
proliferation, which accompanies macrophage differentiation
(Fig. 3D). However, in contrast, stable MOLM-13 cell line expressing
lentiviral vector driven shDMP1_1 (combination of shDMTF1_375 and
shDMTF1_2148) or shDMP1_2 (combination of shDMTF1_888 and
shDMTF1_2248) demonstrated a signiﬁcant gain of proliferative func-
tion upon PMA-induced macrophage differentiation (Fig. 3D). Assess-
ment of DMP1 mRNA disruption in MOLM-13 cells by either
shDMP1_1 or shDMP1_2 showed up to 50% transcript disruption in
the 2 independent cell lines generated (Suppl. Fig. 5B). Lastly, the
promyelocytic leukemia cell line HL-60, reported to not express p53
due to major gene deletions [31], also demonstrated a gain of prolifera-
tive in PMA-derived macrophages expressing the same DMP1 knock-
down constructs (Suppl. Fig. 5C and D). Together, these ﬁndings
indicate that disruption of DMP1 transcript expression promotes gain
of proliferation in macrophages in the presence or absence of p53 and
that ectopic expression of DMP1β induces a similar cellular effect.
3.4. Overall lower human DMP1 mRNA and distinct splice variant expres-
sion in primary acute myeloid leukemias (AML)
Molecular events leading to AML include a block of normal myeloid
differentiation combined with gains of survival and proliferation. The
potential role of DMP1 functioning as a tumor suppressor prompted
us to investigate whether DMP1 mRNA expressions in primary acute
myeloid leukemia (AML) samples, composed of different FAB subtypes,
were altered. To this end, we assessed DMP1 transcript levels in 78 AML
patient samples and, as myeloid cell controls, 5 peripheral blood granu-
locyte and three freshly isolated CD34+ cell samples utilizing qPCR for
total DMP1. DMP1 mRNA levels were given as differences in Ct-values
compared to mRNA levels for the housekeeping genes HMBS and
ABL1. DMP1 mRNA expression levels in AML patient samples were
signiﬁcantly lower than in granulocytes (Fig. 4A; Mann–Whitney U,
P b 0.01), but similar to the CD34+ cells.
Next, we assessed DMP1 mRNA splice variant patterns in 7 primary
AML cell samples of different FAB subtypes (Fig. 4B). Since the human
DMP1 qPCR methodology did not faithfully differentiate among the
three splice variants, a semi-quantitative DMP1 splice variant speciﬁc
RT-PCR assay was used, as described in Material and Methods Section
2.4 and [8]. Theα, β, andγ plasmidswere used as controls and provided
equal band density, thus controlling for RT-PCR performance [24,25].
Band densities from each AML patient sample were measured and α/β
ratios calculated. We found that 5/7 AML patient samples presented
with enhanced expression of DMP1β transcripts relative to DMP1α
(Fig. 4B), with an overall ratio of 0.9 ± 0.1 DMP1α to β transcripts in
all 7 samples, similar to that reported from freshly isolated CD34+
cells, but not lower than differentiating myeloid progenitors [8].
Since AML cells are blocked at early stages of myeloid development
and express lower levels of DMP1 transcripts than granulocytes
(Fig. 4A) and myeloid progenitors [8], we next asked whether the
acute promyelocytic leukemia (APL — the M3 subtype of AML) cell
lines, NB4 and HT93, and 2 primary patient samples were capable of
regulating DMP1 expression during terminal granulocyte differentia-
tion. To promote myeloid differentiation, all-trans retinoic acid-
mediated (ATRA) treatmentwas utilized [32]. After ATRA-mediated dif-
ferentiation of NB4 and HT93 cells to granulocytes, DMP1 mRNA levels
increased 2.3-fold in NB4 cells and 3.5-fold in HT93 cells relative to
the starting mRNA levels (Fig. 4C). This same pattern of increased
DMP1 mRNA levels after ATRA treatment of APL cells was observed in
two APL patients undergoing ATRA therapy (Fig. 4D). These ﬁndings
demonstrate that DMP1 expression is decreased in AML cells, and
DMP1 expression can be increased in APL cells when differentiated.
The results imply that decreased levels of DMP1 transcripts, and en-
hanced DMP1β transcript levels (Fig. 4B) are coincident with a block
in AML differentiation.
4. Discussion
Our original investigations of DMP1 expression in human hemato-
poietic cells uncovered 2 isoforms, β and γ, in addition to DMP1α [8].
The current study demonstrates that while the DMP1γ isoform is inef-
fective in modulating ARF activation or promoting discernable cellular
phenotypes, the DMP1β isoform disrupts ARF activation mediated by
DMP1α with promoter reporters and in ﬁbroblasts. Of note, DMP1β
also inhibited the basal activity of an ARF promoter reporter construct
with a mutated DMP1 binding site. Since the DMP1α form did not acti-
vate the mutated ARF promoter, we speculate that the β-speciﬁc amino
acidsmay lead to a gain-of-function that could impair additional ARF ac-
tivators.Moreover, loss of DMP1 activity in cells, either through targeted
message knockdown with shRNAs or by ectopic expression of DMP1β,
effectively counteracts the cellular growth arrest triggered by either
serum-deprivation or induction of myeloid differentiation, in the pres-
ence or absence of p53. In contrast to normal granulocytes, DMP1 tran-
scripts in AML were decreased. In line with the identiﬁcation of DMP1
isoforms and their potential cellular functions, the presence of mouse
functional β-transcripts, together with the reported β-transcripts in
ferrets, dogs, cats and sheep [33], a recent report of DMP1β transcripts
and protein in breast cancer cells, and tumor promoting activity in
MMTV–DMP1β transgenic mice [9], supports a physiological role for
DMP1-isoforms in many animal species.
In order to understand mechanistically how DMP1β may regulate
DMP1α, we investigatedwhether the DMP1β- and γ-isoforms compete
directly with DMP1α for DNA binding site use. We showed that
both DMP1β and γ isoforms, in contrast to DMP1α, do not bind DNA,
which implies that these isoforms cannot compete directly with
DMP1α for DNA binding. The lack of cellular activity of the DMP1γ iso-
form could be due to its low cellular levels and nuclear retention. It
has been reported that the conserved lysine at position 319, missing
in DMP1β and γ, appears to be necessary for DMP1–DNA interactions
[3,34], consistent with our ﬁndings (Fig. 2B). How might then DMP1β
disrupt the function of DMP1α? Our ﬁndings that co-incubation of
DMP1αwith β reduces DMP1α's binding to DNA suggests an alternative
pathway that may interfere with the formation of α/α interaction and
subsequent binding to the ARF promoter [35]. This phenomenon is not
without precedent, as a number of examples exist for transcription fac-
tors functioning as homodimers and with functional disruption through
heterodimer formation, such as the p73 tumor suppressor, STAT3 and
the human glucocorticoid receptor [36–38]. Cellular co-localization of
α/α and α/β in the nucleus, as visualized with in situ proximity ligation
methodology, supports potential proximal α/α and α/β interactions.
Although our ﬁndings would support heterodimer formation, which is a
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mechanism that is functionally appealing to explain the inhibitorymech-
anism of the β-isoform,we cannot exclude the possibility that the unique
35-amino acid protein domain of the β-isoform binds cellular cofactors
that disrupt DMP1α-induced transcription of DMP1 regulated genes. In
fact, the importance of this unique domain was striking in our experi-
ments, where removing the 35-amino acid protein domain severely im-
paired the function of human DMP1β (Fig. 2A).
Despite the complexity of ARF regulation mediated by DMP1 iso-
forms, we propose a direct role for DMP1β in damping the cellular path-
ways controlling proliferation. We present evidence that ectopic
expression of DMP1β, as well as signiﬁcant downregulation of DMP1α
together with other DMP1 splice variants, result in maintenance of pro-
liferation of 293T, U937 and HeLa cell lines cultured in serum-deprived
media. Moreover, we show that macrophage differentiation induced
growth arrest of PMA-treated U937 cells was ineffective when the
ratio of α/β isoform is inverted through ectopic expression of DMP1β
or through disruption of DMP1 transcript levels. Additionally, the gain
of proliferative function with disruption of DMP1 transcripts in PMA-
induced macrophages was independent of mutated (HL-60 and U937
cells) or functional p53 (MOLM-13 cells). These ﬁndings imply that ec-
topic expression of DMP1β disrupts the delicate DMP1α/β balance, thus
altering cellular proliferation control, possibly through ARF and inde-
pendent of p53.
Our results connect cellular phenotypes resulting from the loss of
DMP1 to that mediated by ectopic expression of DMP1β. The cell lines
used in this study expressed wild type p53 or were p53-deﬁcient either
due to expression of viral oncogenes or p53mutations.We propose that
proliferation in DMP1 disrupted monocytic cells and macrophages
occur via diminished ARF cellular function in a p53-independent fash-
ion.Weber and colleagues have shown that DMP1α remains operation-
al via ARF regulation in p53-deﬁcient mouse cells, where mDmp1α
induces growth arrest in p53-null mouse embryo ﬁbroblasts, but not
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**Mann–WhitneyU, p b 0.01. B) DMP1βmRNA levels relative to DMP1α in primary leukemic patient samples. DMP1 splice variant cDNAswere used as size and efﬁciency controls for the
PCR reaction. C) NB4 and HT93 acute promyelocytic leukemia cells were differentiated in vitro for 4 days using 1 μM all-trans retinoic acid (ATRA). mRNA levels are expressed as n-fold
changes in regulation compared to untreated cells using HMBS mRNA expression as a reference gene. Average values from two experiments are shown. D) Two patients with newly
diagnosed APL t(15;17) were treated with orally administered all-trans retinoic acid (ATRA) at a dosage of 45 mg/m2 daily. DMP1 mRNA expression levels in blast cells were assessed
by qPCR. Values were normalized to HMBS and day 0 as the experimental starting point. E) A model of the oncogenic DMP1β pathway. DMP1α is activated upon oncogenic signaling
and can induce growth arrest via the ARF/MDM2/p53 pathway. In addition, DMP1α can induce p53-independent cell cycle stop via alternative targets of ARF such as CtBP2, Tip60 and
rRNAprocessing or p53.DMP1βmaypromote proliferation bybinding and inhibiting the anti-proliferative DMP1α or byDMP1α-independent pathways, possibly by an as of yet unknown
function of the β-speciﬁc protein domain.
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in p19ARF or p19ARF/p53 double-knockout mouse embryo ﬁbroblasts
[39]. Furthermore, both the activity of the ARF/p53 and the non-p53
pathways are impaired in Dmp1-null and heterozygous mice, suggest-
ing a physiological role of mDmp1α in oncogenic as well as normal
cellular control. p53-independent cell cycle and apoptosis control via
ARF is most likely conducted by a wide range of ARF binding partners,
such as B23/nucleophosmin, DP1 and Tip60 [40–42]. It has been pro-
posed that DMP1β functions independently of the ARF-DMP1 axis [9],
perhaps through direct interaction with p53. This mechanism is not
without precedent as DMP1α has been shown to interact directly
with p53 [7]. However, we cannot dismiss additional as of yet undiscov-
ered target genes/pathways thatmay be important in DMP1β imparting
cellular function. Nevertheless, our ﬁndings demonstrate that ectopic
expression of DMP1β disrupts the delicate DMP1α/β balance, thus
altering cellular proliferation control.
Molecular events leading to AML include both disruption/blocks at
various stages of myeloid differentiation in combination with gains of
survival and proliferation [32]. Recent studies have demonstrated that
low levels of p14ARF are an independent predictor for poor survival in
patients with AML [43]. Although it has been shown that AML1-ETO fu-
sion protein expression represses activation of ARF [20,44,45], most
AML samples demonstrating decreased levels of ARF were not AML1-
ETO positive. We found that DMP1 transcripts are dampened in AML
samples, with levels similar to freshly isolated CD34+ cells, rather
than granulocytes [8]. Furthermore, 5/7 of the AML patient samples
demonstrated DMP1α/β transcript ratios below 1, indicating a greater
abundance of DMP1β over DMP1α, and lower than the DMP1α/β tran-
script ratio of ≥1.5 reported for differentiating myeloid progenitors [8].
ATRA treatment of APL patient samples promoted differentiation to
granulocytes and was coincident with an increase in DMP1 transcripts
to levels similar to normal granulocytes. The increase in DMP1β tran-
script abundance in AML cells may reﬂect a myeloid stage speciﬁc con-
dition associated with reduced tumor suppression and increased
proliferation. Mallakin and colleagues have proposed that DMP1 is
haplo-insufﬁcient for tumor suppression in human lung and breast can-
cer [46–48]. In addition, the authors found that DMP1β over α tran-
script ratios were increased 54.8% in ER+/HER2- and 42.9% in triple
negative primary breast tumors as compared to adjacent normal breast
tissue [9]. A recent study by the same group has shown that increased
DMP1β transcripts and proteins levels in breast cancer tumors correlat-
ed with increased relapse rate [9]. Future evaluations of DMP1 tran-
script variant levels and protein isoform amounts in additional types
of human hematopoietic and solid cancers should prove insightful as
to their involvement in speciﬁc cancer types.
We originally demonstrated that DMP1β is expressed during early
stages of hematopoietic differentiation [8] and now show that DMP1β
has the potential to blunt DMP1α regulation of ARF during myeloid
cell differentiation. A recent publication by Kobayashi and Srour utiliz-
ing Dmp1-null and -hemizygousmice demonstrated enhanced prolifer-
ation in the stem and progenitor cell populations [18]. Both our earlier
study and Kobayashi's and Srour's study underscore the importance of
DMP1 in regulation of normal hematopoietic cellular proliferation and
differentiation. Our current ﬁndings extend the cellular role of DMP1
isoform regulation by demonstrating that loss of DMP1 isoforms or in-
creased expression of DMP1β result in a similar phenotype: Increased
cell proliferation of myeloid cells. Our ﬁndings on AML, as well as
those of Maglic and colleagues in breast cancer [9], point out a possible
pathological role for the dysregulation of DMP1 isoforms. The ability
of DMP1β to negatively regulate ARF places it in the ranks of other
negative ARF regulators, such as Bmi-1, JunD, Tbx-2/3, Twist, and p53
[49–52]. It is tempting to speculate that a cellular balance of DMP1α/β
ﬁne-tunes ARF regulation during normal cellular differentiation and
maintains growth/proliferation during differentiation by counter-
balancing the potent effects of DMP1α, as shown in the diagram in
Fig. 4E. Although limited human cancer samples have been evaluated
for DMP1 splice variant expression to date, it is intriguing to propose
that increased expression of DMP1β or loss of DMP1αwill have similar
functional consequences.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbagrm.2015.07.009.
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